Maternal and Fetal Research Unit, King's College London, Division of Reproduction and Endocrinology, St Thomas' Hospital, London SE1 7EH, United Kingdom.
Eur J Obstet Gynecol Reprod Biol. 2009 Oct;146(2):180-3. doi: 10.1016/j.ejogrb.2009.06.021. Epub 2009 Jul 19.
To determine clinicians' indications for, and actions following, fetal fibronectin testing in both symptomatic and asymptomatic women between 23(+0) and 34(+6) weeks' gestation.
Following clinician education of the predictive ability of fetal fibronectin testing, results of all fetal fibronectin tests done at St Thomas' Hospital over a 6-week period were analysed. Clinicians were asked if the result changed management and if a reciprocal result would have altered management.
Ninety-seven fetal fibronectin tests were conducted of which 21 (22%) were positive. Follow-up was done for 91 tests of which 25 (28%) test results directly changed management; 81 (89%) test results had the potential to change management independent of the test result.
The results of fetal fibronectin testing directly influenced management in a significant number of patients. A large number of women were asymptomatic at testing. Fetal fibronectin testing could be offered more widely and has the potential to benefit patient management.
确定临床医生在 23（+0）至 34（+6）孕周之间有症状和无症状的女性中进行胎儿纤维连接蛋白检测的适应证和检测后的处理措施。
在对临床医生进行胎儿纤维连接蛋白检测的预测能力的教育之后，分析了在圣托马斯医院进行的所有胎儿纤维连接蛋白检测的结果。询问临床医生检测结果是否改变了处理措施，如果得到相反的结果是否会改变处理措施。
共进行了 97 次胎儿纤维连接蛋白检测，其中 21 次（22%）为阳性。对 91 次检测进行了随访，其中 25 次（28%）检测结果直接改变了处理措施；81 次（89%）检测结果具有独立于检测结果改变管理的潜在可能性。
胎儿纤维连接蛋白检测的结果直接影响了大量患者的管理。大量女性在检测时无症状。胎儿纤维连接蛋白检测可以更广泛地提供，并有可能有利于患者管理。
